In the Phase III SENTRY trial of selinexor plus ruxolitinib versus placebo plus ruxolitinib in JAK inhibitor-naïve myelofibrosis, which statement best describes the results presented at SOHO?
Both co-primary endpoints, SVR35 and absolute reduction in mean total symptom score (TSS), were met at week 24.
The SVR35 co-primary endpoint was met, the TSS co-primary endpoint was not, and an early overall survival benefit was seen with the combination.
The TSS co-primary endpoint was met, but there was no significant difference in SVR35 between the two arms.